Two new studies delving into the relative safety of biologic drugs prescribed for rheumatoid arthritis (RA) have concluded that real-world applications of abatacept and tumor necrosis factor inhibitors (TNFi’s) are comparable to more conventional therapies in their associated risk of serious infections. Triple Therapy One study, in Arthritis Care & Research, found the risk of…
![Shidlovski / shutterstock.com](https://www.the-rheumatologist.org/wp-content/uploads/2020/05/THR_0520_pg42a-150x150.png)